Amgen UK’s Chris Fox: Up for the Challenge
Christine (Chris) Fox, VP general manager UK and Ireland at Amgen discusses the rationale behind taking on the management of a UK affiliate in challenging times and the specificities of…
Address: Janssen, 50-100 Holmers Farm Way, High Wycombe, Buckinghamshire, HP12 4EG, United Kingdom
Tel: +44 (0) 1494 567567
Web: http://www.janssen.co.uk/
In 1947, Ortho Pharmaceuticals was brought into the Johnson & Johnson group of companies and set up a UK base in Lane End, Buckinghamshire.
Johnson & Johnson’s pharmaceutical interests expanded over the next decades with the addition of the Swiss company Cilag Chemie in 1959 and the Belgian company Janssen Pharmaceutica in 1961. Both of these companies had grown from small research laboratories into successful multinationals.
Ortho moved to a site in Saunderton, Buckinghamshire in the early 1950s. Janssen established its first British offices in Marlow, Buckinghamshire, in 1974 and moved to Grove in Oxfordshire a decade later.
Ortho became Ortho Cilag in 1982 and then Cilag in 1988. On 1st January 1995, Cilag and Janssen merged to become Janssen-Cilag Ltd and all operations were transferred to the Saunderton site. In May 2008, the company moved to new offices in High Wycombe.
In September 2000, Ortho Biotech was established, a company specialising in treatments for conditions such as renal disease and cancer.
Tibotec was established in 1994 as a drug discovery laboratory, it evolved to a fully integrated pharmaceutical company focussing on the discovery and the development of new drugs for infectious diseases. In April 2002, Tibotec was acquired by Johnson & Johnson and became a division of Janssen-Cilag.
In 2010, Janssen-Cilag became Janssen and now employs more than 400 people. Its head office is in High Wycombe, Buckinghamshire and also has an office in Dublin.
Janssen is one of the world’s leading research-based pharmaceutical companies, with operations throughout the world. In the UK, Janssen employs more than 400 people.
The company is committed to delivering great medicines and has introduced a range of innovative treatments that can make an important difference to the lives of patients with serious health conditions such as schizophrenia, epilepsy, multiple myeloma and HIV/AIDS. Janssen has one of the strongest development pipelines in the industry with research now focusing on five key areas. These key areas are: neuroscience, oncology, immunology, metabolism and infectious diseases.
Christine (Chris) Fox, VP general manager UK and Ireland at Amgen discusses the rationale behind taking on the management of a UK affiliate in challenging times and the specificities of…
A spinout from the Roslin Institute that created Dolly the Sheep, Roslin CT is a cell and gene therapy CDMO, with a unique positioning in the field today. Its CEO,…
Jonny Ohlson, founder & CEO of Touchlight, discusses the genetic medicine revolution and the role of Touchlight in disrupting the field with its revolutionary DNA technology. You founded Touchlight Genetics…
Dr. Geoffrey Guy, chairman and founder of cannabinoid medicine pioneer, GW Pharma, outlines the potential benefits that Brexit could bring to the UK’s life sciences industry and the evolution of…
KaNDy Therapeutics, a UK-based biotech has raised £25 million to finance the Phase 2b trial of their breakthrough product in Women’s Health. Our investors and the KaNDy management team are united…
Sterling Pharma Solutions is a rapidly growing GMP contract API manufacturer based out of Dudley, Cramlington in the Northeast of England. The company was set up in its current structure…
Offering genomic sequencing and analysis, Congenica operates in the exciting world of genomic diagnosis, with a particular focus on rare diseases. Its CEO David Atkins describes the potential of Congenica’s…
Sean Richardson discusses Alexion’s focus on rare and ultra-rare diseases, the level of support for these therapies from the UK government, awareness raising, diagnostics, and his future priorities. …
With over 30 years of experience in the life sciences industry, Angela McFarlane explains why the UK will not be removed from its position in the top 3 for new…
For Ipsen, the UK is one of three global hubs, with manufacturing in Wales in which it is continuously investing, as well as large-scale R&D activities near Oxford. Ipsen’s general…
Brexit, Brexit, Brexit. It’s all anyone can talk about and yet nobody can tell you with certainty what to expect. As the UK’s impending withdrawal from the European Union looms…
Professor David Garway-Heath, a specialist in glaucoma, talks with us about the screening devices of the future, low awareness of glaucoma as a chronic disease and collaboration in training and…
See our Cookie Privacy Policy Here
